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Abstract: One of the unique features of prenatal alcohol exposure in humans is impaired 
cognitive and behavioral function resulting from damage to the central nervous system 
(CNS), which leads to a spectrum of impairments referred to as fetal alcohol spectrum 
disorder (FASD). Human FASD phenotypes can be reproduced in the rodent CNS following 
prenatal ethanol exposure. Several mechanisms are expected to contribute to the detrimental 
effects of prenatal alcohol exposure on the developing fetus, particularly in the developing 
CNS. These mechanisms may act simultaneously or consecutively and differ among a 
variety of cell types at specific developmental stages in particular brain regions. Studies 
have identified numerous potential mechanisms through which alcohol can act on the fetus. 
Among these mechanisms are increased oxidative stress, mitochondrial damage, interference 
with the activity of growth factors, glia cells, cell adhesion molecules, gene expression 
during CNS development and impaired function of signaling molecules involved in neuronal 
communication and circuit formation. These alcohol-induced deficits result in long-lasting 
abnormalities in neuronal plasticity and learning and memory and can explain many of  
the neurobehavioral abnormalities found in FASD. In this review, the author discusses  
the mechanisms that are associated with FASD and provides a current status on the 
endocannabinoid system in the development of FASD. 
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1. Introduction 
The influence of alcohol use during pregnancy on children has received widespread research 
attention since early reports that prenatal alcohol exposure can have devastating and enduring 
consequences [1]. Among the many potential outcomes of prenatal alcohol exposure, alterations in the 
developing brain and the resulting lifelong neurobehavioral deficits have been the most devastating. 
One of the many recognized consequences of prenatal alcohol exposure is fetal alcohol syndrome 
(FAS) [2], which is characterized by pre- and postnatal growth deficiencies, craniofacial anomalies and 
central nervous system (CNS) dysfunction. FAS is now recognized as an important cause of intellectual 
disabilities and behavior problems in many countries [3–7]. However, over the last 35 years, it has 
become clear that FAS is not the only outcome resulting from prenatal alcohol exposure. Indeed, the 
term fetal alcohol spectrum disorders (FASD) [8] has been used to emphasize the continuous nature of 
the effects of prenatal alcohol exposure, with FAS at the more severe end of the spectrum. While 
literature regarding the behavioral profile of FASD is relatively limited [9], reported deficits suggest 
that FASD is one of the main causes of intellectual disability in Western nations [10] and is accompanied 
by widespread neuropsychological deficits such as verbal learning/recall abilities [11,12], including 
deficits in learning and memory [13,14]. These substantial neuropsychological deficits create many 
daily challenges for individuals with FASD. However, the cognitive deficits of FASD are not fully 
understood, and a characteristic outline has not been identified. This review will provide a comprehensive 
summary of the neurobehavioral effects of heavy prenatal alcohol exposure. Supporting studies from 
animal model systems with an emphasis on the molecular events mediated by the endocannabinoid 
system resulting in brain-behavior associations are included when appropriate. 
1.1. Influence of Developmental Stage, Amount and Pattern of Alcohol Use on  
Neurobehavioral Outcome 
The consequences of maternal alcohol use during pregnancy on the neurobehavioral outcome of 
children are dependent on several factors, including the amount and pattern of alcohol consumption  
as well as the developmental timing of exposure. In most cases, the amount of alcohol consumed is 
correlated with the severity of the outcome [15,16]. However, the pattern of alcohol exposure can often 
undermine these effects, with binge-like exposures resulting in more severe deficits than chronic 
exposure [17,18]. Developmental timing of the exposure is also important. Alcohol exposure at different 
periods of fetal development can greatly influence the pattern and severity of the structural and functional 
abnormalities [19]. In addition, several other factors may contribute to this variation in the consequences of 
maternal drinking. These factors include, but are not limited to, the following: differences in maternal 
metabolism, differences in genetic susceptibility, and variation in the vulnerability of different brain 
regions. Nevertheless, factors that alter the peak blood alcohol concentration (BAC) experienced by the 
embryo or the fetus (e.g., maternal drinking patterns and maternal metabolism) are most likely to affect 
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the occurrence and severity of alcohol-induced developmental brain disorders. Unfortunately, this level 
of detail is often difficult to document, particularly in retrospectively recruited samples, and individual 
studies provide varying degrees of detail concerning the levels and patterns of exposure. These issues 
highlight the modifying variables that contribute to the considerable range of phenotypes presented in 
children with FASD. 
1.2. Neurobehavioral Abnormalities in Children with FASD 
FASD affects an estimated prevalence of as high as 2%–5% in the United States and several  
Western European countries [20] and is the leading preventable cause of mental retardation [8]. 
Although publicity campaigns have encouraged women to stop alcohol consumption once they know 
that they are pregnant, data from a US national survey indicated that 13% of women continue to use 
alcohol during pregnancy (see [21]). 
Prenatal alcohol exposure has been associated with widespread neuropsychological deficits across several 
domains (Table 1), including general intelligence, memory, language, attention, learning, visuospatial 
abilities, executive functioning, fine and gross motor skills and social and adaptive functioning [12]. 
Many FASD individuals exhibit impaired intellectual abilities and growth retardation [22], although 
children with a diagnosis of FAS tend to have more severe impairments compared to those who were 
exposed prenatally to alcohol but do not have sufficient dysmorphic features for a diagnosis [23]. However, 
not all individuals diagnosed with FAS are intellectually disabled (IQ score < 70), and intellectual 
disability is not a necessary criterion for the diagnosis of FAS. The average IQ estimate of children 
with prenatal alcohol exposure is 70 for those with FAS [7] and 80 for nondysmorphic children [23]. 
However, fewer studies have been performed on the intellectual abilities among individuals with 
moderate levels of alcohol exposure, and these results have been inconsistent [16,24–27]. The 
discrepancies among studies with moderate levels of exposure warrant the need for further research 
and the importance of considering a variety of factors as described in the proceeding section when 
evaluating studies. 
Table 1. Summary of neuropsychological abnormalities found in individuals with fetal 
alcohol spectrum disorders (FASD) when compared to typically developing children. 
Cognitive Function FASD References 
General Intelligence Lower IQ (~70) [7,23,28] 
Executive Function 
Impaired executive functions  
such as planning, fluency and working memory 
[14,29–34] 
Learning and memory 
Verbal 
Impaired initial learning without affecting retention of  
information already learned due to implicit learning strategies. 
[12,35–40] 
Nonverbal 
Impaired nonverbal learning and memory but  
impairment of retention of information is inconsistent. 
[29,36,39,41–44]
Motor function Deficits in motor abilities and visual-motor tasks. [11,35,42,45–51]
Attention and hyperactivity Deficits in attention and exhibit hyperactivity. [10,48,52–60] 
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A number of clinical studies have also reported learning and memory deficits in children with heavy 
prenatal alcohol exposure. Prenatal alcohol-exposed children display poorer academic achievement 
and higher learning disability rates than control children [61], which may relate to impairments in their 
verbal and non-verbal learning and memory [35–37]. These deficits were present in both children with 
and without the dysmorphic features of FAS [12,36]. Some studies have suggested that the long-term 
retention of verbal information is intact in alcohol-exposed children but that the initial encoding processes 
may be impaired [36,38]. In addition to non-verbal memory difficulties, children with FASD showed 
visuospatial processing deficits [35], suggesting damage and abnormalities in the frontal-subcortical 
pathway. Attention deficits [62,63] and attention deficit hyperactivity disorder (ADHD) [64] were also 
frequently found in FASD children. A recent collaborative study also suggested that executive function 
and spatial processing were particularly sensitive to prenatal alcohol exposure [52]. Executive functions 
are regulated by the frontal-subcortical circuits, which involve projections from the frontal lobes to the 
basal ganglia and thalamic nuclei [65]. These regions have been found to be affected by prenatal alcohol 
exposure [66,67]. In addition, FASD children have social and adaptive deficits because they are  
more likely to be rated as hyperactive, disruptive, impulsive or delinquent compared to non-exposed  
children [68,69]. Furthermore, children with prenatal alcohol exposure have difficulty resolving 
conflicts and in anticipating the consequences of their actions [70,71], suggesting the challenges that 
children with FASD face in interacting with peers. 
In summary, the phenotype of children with FASD is characterized by social, behavioral, and 
language problems that disrupt interactions with peers and appear to be influenced by task complexity. 
In addition to these disabilities, neuropsychological problems in planning, inhibition, self-regulation, 
and attention and memory potentially contribute to the challenges faced by these children in school 
settings. In particular, children with FASD may suffer from social and academic situations because 
their deficits interfere with their ability to be sufficiently engaged. Student engagement, inferred from 
performance (attention, work completed, appropriate participation), is key to motivation and, ultimately, 
learning or mastering knowledge or skills [72]. These observations highlight not only the importance 
in identifying FASD at early ages, but also the provision of specific treatments to address this 
developmental disability because early identification and treatment have been demonstrated to be 
protective against more serious secondary disabilities [73–75]. Despite four decades of progress, 
research on FASD and its treatment continue to be hampered by a lack of specificity in the behavioral 
diagnostic criteria and a limited understanding of the cellular and molecular substrates of cognitive 
deficits (e.g., attention, memory, executive functioning) caused by heavy prenatal alcohol consumption. 
Finally, research on the biomarkers of fetal alcohol damage may help to improve the future of children 
affected by prenatal alcohol exposure. 
1.3. Neurobehavioral Abnormalities in Animal Models of FASD 
Animal models provide rigorous experimental control over numerous potentially confounding 
variables as well as control of the dose and timing of the alcohol exposure. In addition, animal models 
have the advantage of non-confounding multiple factors, which may be independently manipulated.  
In contrast, causal conclusions are difficult to reach in human studies due to the clustering of negative 
events. For example, alcohol consumption and smoking tobacco are often strongly associated with 
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each other, and alcohol use usually affects nutrition intake in people. However, to relate animal models  
to human development, the relative states of brain development at times of alcohol exposure need to be 
carefully considered. Some of the behavioral and anatomical outcomes discussed above have also been 
reported in animal models of FASD. A number of researchers have extended the findings in humans to 
animal research using tests that have been found to be sensitive to hippocampal function [41,76–86]. 
Prenatal alcohol exposure has been shown to affect embryonic development, which varies 
depending on the severity, duration, and frequency of exposure of ethanol during gestation [87–89]. 
During this period, the use of alcohol prevents the proper blastocyst implantation in the uterus, resulting 
in an increased rate of resorption or early termination of the pregnancy, which generally occurs before 
a woman realizes she is pregnant. In the third week after fertilization, specific alcohol-induced birth 
defects begin to affect the developing embryo [90–93]. Between the third and sixth week after fertilization, 
when neurulation occurs, the cranial neural crest cell population is vulnerable to alcohol-induced 
damages [94], which are related to facial abnormalities characteristic of FAS. From the third week 
through the third trimester, the cellular progenitor pools, known as radial glia, which will give rise to 
the CNS, become vulnerable to the effects of alcohol and result in morphological abnormalities and  
an overall reduction in white matter within the brain [95,96]. Specific damage to the brain continues  
in the sixth and seventh week following fertilization, after the brain has begun to divide into vesicles.  
The corpus callosum, a midline structure responsible for communication between the left and right 
hemispheres of the brain, has been shown to be vulnerable to alcohol at this stage of development [97]. 
The eighth week after fertilization is the end of the embryonic stage and the beginning of the fetal 
stage of pregnancy. At this stage, the developing brain remains vulnerable to prenatal exposure to 
alcohol, particularly in the formation of the cerebellum, and the fetus remains vulnerable in terms of 
prenatal growth restrictions. The cerebellum and hippocampus are vulnerable to the neurotoxic effects 
of alcohol [98], particularly when alcohol exposure is limited to the third trimester equivalent in the rat 
(i.e., the first postnatal week) [98,99]. Purkinje cells within the cerebellum [100] appear most 
vulnerable to the effects of alcohol prior to the 7th postnatal day (PD) [101], while alcohol exposure 
encompassing all of gestation (gestational days (GD)1–22) or limited to either PD 4–9 or PD 7–9 
results in CA1 pyramidal cell reduction within the hippocampus [80,82,84,102–105]. Limiting alcohol 
exposure to PD 7–9, therefore, is likely to result in significant hippocampal targeting relative to the 
cerebellum and may result in severe learning and memory deficits [106–112]. 
1.3.1. Potential Mechanisms Responsible for FASD 
Anatomical alterations associated with brain dysfunction may range from a gross reduction in  
brain volume to deficits in cell number in a particular brain region to cellular modifications of individual 
neurons, resulting in alterations in the communications among neuronal cells. These alterations can 
have a long-term detrimental effect on behavioral and cognitive development. Experimental evidence 
has demonstrated that ethanol exposure during brain development could affect several molecular, 
biochemical and cellular events, which participate in the proper formation of brain structure. Thus,  
at the cellular level, and depending on the time and amount of alcohol exposure, ethanol could  
induce deficits in cell proliferation, migration, growth and differentiation and may cause apoptotic 
neurodegeneration. For example, alcohol exposure during early embryonic development, when cells 
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undergo rapid division, causes a reduction in the number of cells generated [113], including neural 
progenitor cells [114–116], abnormal neuronal migration and may cause subsequent cell  
death [117,118]. However, if alcohol exposure occurs during the cell differentiation [119,120] and 
synaptogenesis period [121], it may cause robust neurodegeneration [111,112,121–124] leading to the 
loss of synapses. These results support the notion that ethanol exerts its effects by multiple actions at 
different sites involving several mechanisms. 
Several major molecular mechanisms have been identified as potential candidates responsible for 
FASD [98,125,126]. These mechanisms are likely to participate at different stages of brain development 
and/or with different doses of ethanol. The major probable mechanisms include the following: (1) alterations 
in the regulation of gene expression (e.g., expression of anandamide (AEA) and 2-arachidonylglycerol 
(2-AG) synthesizing enzymes, 2-AG metabolizing enzyme, cannabinoid receptor type 1 [111,127], 
homeobox gene, histone methyl transferase, altered histone and DNA methylation [109,110,124,128–132], 
and microRNAs (miRNAs) [133,134]; (2) interference with mitogenic and growth factor responses 
involved in neural stem cell proliferation, migration and differentiation [135–137]; (3) disturbances  
in the molecules that regulate cell–cell interactions (e.g., L1, NCAM, growth factors) [138–143];  
(4) activation of the molecular cascade, which regulates cell survival or cell death (growth factor 
deprivation, oxidative stress, apoptotic signaling through caspase-3 activation, H3 histone methylation 
mediated histone degradation, suppression of N-Methyl-D-aspartate (NMDA), glutamate and  
gamma-amino butyric acid-A (GABAA receptors) [111,124,144–150]; (5) abnormalities in glial 
proliferation, differentiation and function [95,151] and (6) suppression of the mitogen-activated protein 
kinase (MAPK) pathway via enhanced endocannabinoid signaling [110,111,127]. This last mechanism 
is supported by CB1 receptor antagonist and CB1 receptor null mice studies revealing the contribution 
of this signaling system to neuronal loss through caspase-3 and NMDA receptors, synaptic plasticity 
and learning and memory abnormalities found in an FASD animal model [110,111,127]. Due to the 
potential contribution of this novel mechanism to brain development, learning and memory loss with 
FASD, we will describe the evidence demonstrating that the endocannabinoid signaling system is an 
important potential target involved in the development of FASD. 
1.3.2. Role of the Endocannabinoid System during Brain Development and in Ethanol-Induced  
Brain Abnormalities 
Within the last two decades, cannabinoid research has received tremendous attention due to the 
breakthrough and discovery of the receptors that bind delta-9-tetrahydrocannabinol (Δ9-THC) (cannabinoid 
receptors) and their endogenous ligands, endocannabinoids (ECs) (endocannabinoid system) in animal 
tissues (for a recent review see [152]). This emerging body of research has revealed multiple ways in 
which the EC system functions to regulate synaptic neurotransmission in various brain areas [153–155] 
in the developing and adult brain. Growing research has demonstrated vital functions for EC signaling 
in molecular pathways that underlie both short- and long-lasting alterations in synaptic strength [156,157]. 
In fact, the critical involvement of ECs in some mechanisms of synaptic neurotransmission may 
change the current working cellular models of learning and memory. These models may be vital in 
understanding and providing potential treatment for the disease conditions in which the EC system 
plays an important role. 
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Potential Role of Endocannabinoids and Their Metabolic Enzymes 
ECs consist of lipid signaling molecules that bind to and activate cannabinoid receptors. These lipid 
compounds are formed from phospholipid precursors [158–163] within cells throughout the body and are 
released from these cells on demand in a nonvascular manner to act in a paracrine fashion [158,160–164]. 
In 1992, anandamide (arachidonylethanolamide, AEA) was first identified as an endogenous 
cannabinoid. Its name is derived from the Sanskrit word, ananda, which means “internal bliss”, making a 
reference to its chemical structure (the amide of arachidonic acid and ethanolamine) [165]. Subsequently, 
another endogenous cannabinoid receptor ligand, 2-arachidonylglycerol (2-AG), was discovered and 
characterized [166,167]. The third ether-type EC, 2-arachidonylglycerol ether (noladin ether), was 
isolated from the CNS and shown to display pharmacological properties similar to AEA [168].  
The fourth type of EC, virodhamine, in contrast to the previously described ECs, is a partial agonist with 
in vivo antagonist activity on the CB1 receptor [169]. The fifth type of EC, N-arachidonyl-dopamine 
(NADA), not only binds to the CB1 receptor but also stimulates vanilloid receptors (VR1) [170]. 
Importantly, except for AEA and 2-AG, to date, there is little evidence regarding the physiological 
actions of these compounds. 
AEA is thought to be synthesized by several pathways (see review for details [171]). Importantly, 
there is strong evidence for a calcium dependence in both of these synthesis steps, which may underlie 
the requirement for postsynaptic Ca2+ in specific forms of depolarization-induced synaptic plasticity  
(For details see [157]). Biosynthesis of AEA from membrane phospholipid precursors is catalyzed  
by several enzymes. The most well-studied of these is N-acylphosphatidylethanolamine-specific 
phospholipase D (NAPE-PLD; [172,173]), but others include glycerophosphodiesterase (GDE1) [174], 
abhydrolase domain 4 (ABHD4) [175] and phosphatase PTPN22 [176] (Figure 1). In our recent study, 
we found that NAPE-PLD protein levels were significantly lower during the synaptogenic period of 
mouse brain development and gradually increased to adult levels [111]. Similar patterns of NAPE-PLD 
expression were also found during rat brain development [177]. Overwhelming data suggested that the 
lack of NAPE-PLD significantly reduced the levels of AEA and other NAE [178,179] in the brain, 
although some controversy exists on whether NAPE-PLD contributes to the formation of AEA in the 
brain [180]. Interestingly, studies have suggested a significant reduction in the accumulation of brain 
NAEs, including AEA, in GDE1/NAPE-PLD double KO mice treated with an FAAH inhibitor that 
blocks NAE degradation [181]. Our study suggested that postnatal ethanol treatment enhanced AEA 
levels via transcriptional activation of both the NAPE-PLD and GDE1 genes, resulting in the enhanced 
expression of NAPE-PLD and GDE1 mRNA and proteins in neonatal mouse brain regions [111]. 
As a putative neuromodulator, AEA released into the synaptic cleft is expected to be rapidly inactivated. 
In general, two mechanisms are known that could remove ECs from the synaptic cleft to ensure rapid 
signal inactivation: re-uptake or enzymatic degradation. AEA is inactivated by reuptake [182,183] via an 
uncharacterized membrane transport molecule, the “AEA membrane transporter” (AMT) [163,182,184–188], 
and subsequent intracellular enzymatic degradation. AEA is metabolized into arachidonic acid and 
ethanolamine via the action of the fatty acid amide hydrolase (FAAH), and this activity plays a 
significant role in the rapid clearance of AEA from extracellular compartments [189,190]. In addition, 
fatty acid binding proteins (FABPs) are suggested to serve as intracellular carrier of AEA and play an 
important role in the pathway for AEA inactivation by FAAH. Inhibition of FAAH activity by 
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pharmacological blockade or genetic ablation has been shown to cause an accumulation of AEA in the 
brain [191–193]. Similar to FAAH inhibition, inhibitors of FABPs also reduce hydrolysis of AEA and 
its uptake into cells, raising levels of extracellular AEA [194–197]. In addition to hydrolysis by 
FAAH, AEA is metabolized by COX-2, LOX and cytochrome P450 [187,198–200]. Further research 
is required to elucidate the precise mechanism and enzymes involved in this pathway of AEA 
metabolism. It was previously shown that the FAAH distribution during postnatal development was 
very similar to the adult pattern [201]. In our study, postnatal ethanol treatment did not considerably 
alter either the FAAH protein or the mRNA levels in neonatal brain regions [111]. Moreover, FAAH 
has been detected in radial glia during late gestation and postnatal periods [202]. These distribution 
patterns of FAAH, together with the EC control of astrogliogenesis [202], suggest the involvement of 
EC signaling in neural progenitor differentiation in vivo. A fine balance between progenitor cell 
proliferation and programmed death ensures the generation of adequate quantities of neural cells 
during brain development. 
The second widely recognized endogenous CB1 agonist is 2-AG, which was characterized soon  
after the discovery of AEA [166,167]. 2-AG has been characterized as a unique molecular species of 
monoacylglycerol isolated from both the canine gut [166] and rat brain [203], where it presumably 
functions as an endogenous cannabinoid receptor ligand. 2-AG biosynthesis occurs via two possible 
routes in neurons (see recent review [204]). DAGL-α and β both contribute to a large extent the 
regulation of steady-state levels of 2-AG in the brain and other tissues. However in mice lacking 
DAGL-α, 2-AG levels are reduced by up to 80% in the brain and up to 50% in the DAGL-β null 
mouse brain [205]. DAGL-α and β are expressed lower during early development and gradually 
increase throughout development to adulthood [127]. 2-AG, similar to AEA, is found in a variety of 
tissues throughout the body and brain and appears to be released from cells in response to specific 
stimuli. Although the 2-AG concentration in the rodent brain is in the nanomolar range, which is one 
hundred times higher than that of AEA, it is 20 times less potent than AEA at the CB1 receptor [166]. 
2-AG is also inactivated by reuptake [182,183] via an uncharacterized AMT [163,182,184–188], and 
subsequent intracellular enzymatic degradation [158,189,206] by monoacylglycerol (MAGL) lipase, 
similar to other monoacylglycerols [207]. MAGL expression levels are lower during early development 
and gradually increase throughout development to adulthood [127]. Furthermore, 2-AG is metabolized 
by enzymatic oxygenation of 2-AG by COX-2 into PGH2 glycerol esters. The biological activity and 
role of oxygenated 2-AG have yet to be determined. Furthermore, postnatal ethanol treatment did  
not significantly enhanced 2-AG levels in neonatal brain regions. Taken together, these findings raise 
an important question of whether AEA and 2-AG may exhibit distinct functions and warrant future 
studies to understand their specific role during brain development. In our recent studies postnatal 
ethanol treatment consistently enhanced DAGL-β and MAGL, resulting in no significant change in  
the 2-AG levels [127]. Although these events are not economical to cells’ overall function, these 
observations suggest that the enhancement of AEA over 2-AG by postnatal ethanol constitutes an 
example of the generation of unique cellular responses depending on the environment of the cell. 
  




Figure 1. The potential enzymes involved in anandamide (AEA) biosynthesis. Stimulation 
of G-protein coupled receptor (GPCR) mediated adenylate cyclase and cAMP-dependent 
protein kinase (protein kinase A, PKA) potentiate N-acyltransferase (Ca2+-dependent 
transacylase) (NAT). A fatty arachidonic acid chain is transferred by NAT from the  
sn-1 position of phospholipids (phosphoglycerides, PG) to the primary amine of 
phosphatidylethanolamine (PE) in a Ca2+-dependent manner, forming an N-arachidonyl 
phosphatidylethanolamine (N-ArPE). This N-ArPE intermediate is then hydrolyzed by a 
phospholipase D (PLD)-like enzyme to generate AEA. In addition, potential alternative 
pathways for AEA formation from N-ArPE through 2-lysoNArPE and pAEA catalysed by 
sPLA2, lyso-PLD, ABDH4, GDE1 or PTPN22 and SHIP2 are shown (see text for details). 
Once synthesized, AEA can be metabolized into ethanolamine (EA) and arachidonic acid 
(AA) or transported to the outside of the cell through a process that has not yet been well 
characterized. Fatty acid binding proteins (FABPs) serve as intracellular carrier of AEA 
and play an important role in the AEA degradation by FAAH. EMT, ECmembrane transporter. 
The molecular distribution of EC metabolism and their receptor systems during brain development 
suggest that ECs may effectively regulate cellular specification programs [208]. A broad range of 
developmentally regulated receptors and ion channels [209–211] has suggested divergent roles of  
EC signaling during brain development. AEA and 2-AG levels vary substantially throughout prenatal 
development [212,213]. In the beginning stages, between days four and six of pregnancy, AEA in the 
uterus enables embryo implantation [214]. AEA levels are low in the brain at midgestation, and their 
levels gradually increase throughout the perinatal developmental period until adult levels are reached [212]. 
Similar to adult brains, 2-AG concentrations (2–8 nmol/g tissue) exceed those of AEA (3–6 pmol/g 
tissue) throughout brain development [212,213]. Importantly, fetal 2-AG levels are similar to those in 
young and adult rat brains, with a remarkably distinct peak on the first day after birth [212,213]. It has 
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become increasingly evident that ECs and related lipid mediators regulate neural progenitor commitment, 
survival [202,215,216] and synaptic connectivity in the developing brain [217,218]. 
ECs have also been shown to regulate neuronal migration, suggesting a role in specifying the 
morphological, physiological and molecular characteristics that occur during terminal neuronal 
differentiation. AEA and WIN552122 and cooperatively with brain-derived neurotrophic factor (BDNF), 
a principal pro-differentiating neurotrophin, induce migration of GABA-expressing interneurons in the 
embryonic cortex [219]. Similarly, Δ9-THC increased the density of cholecystokinin-expressing 
interneurons in the rat hippocampus in vivo [219]. AEA [219] and WIN552122 [220] strongly inhibited 
neurite formation and elongation in GABA-expressing interneurons. In these studies, AEA abolished 
the morphogenic potential of BDNF. Similarly, cannabinoids, including Δ9-THC, antagonized  
forskolin-induced synaptogenesis in cultured hippocampal neurons [221]. In N1E-115 neuroblastoma 
cells, AEA and HU210 reduced the rates of neurogenic differentiation [222]. These morphological 
changes were mediated through the Rho family of small guanosine triphosphatases and spatially 
controlled its activation, which regulated cytoskeletal integrity [223]. In contrast, the synthetic 
cannabinoid, HU210 promoted neurite outgrowth in Neuro 2A cells via Gαo/i-mediated degradation of 
Rap–GAPII and the subsequent activation of Rap1 [224]. 2-AG also stimulated neurite outgrowth in 
cerebellar neurons through a mechanism that was dependent on intrinsic diacylglycerollipase (DAGL) 
activity within axonal growth cones, whereas CB1 receptor antagonists abolished N-cadherin- and  
Fgf8-induced neurite extension [225]. These observations indicated that EC signaling might regulate 
aspects of growth cone differentiation and axon guidance [226]. Further support for the potential role of 
ECs in the regulation of neuritogenesis was obtained from the similar functional effects of other lipid 
mediators such as lysophosphatidic acid and sphingosine-1-phosphate [222]. Further research is 
required to understand the precise molecular events by which ECs regulate dendritic and axonal 
development. Identification of ECs and the characterization of their metabolic enzymes and second 
messenger signaling cascades will enable a better understanding of the physiological role of EC 
signaling and will reveal the neural basis of developmental defects that are imposed by prenatal drug abuse 
including ethanol. 
A Major Role of Cannabinoid Receptors and Their Signaling 
Evidence for the existence of a marijuana receptor has been demonstrated since the 1980s [227,228].  
It has now been shown that cannabinoids consist of two specific receptor subtypes, known as CB1 and 
CB2, which have been cloned. Evidence for a third receptor (“CB3” or the “AEA receptor”) in brain 
and endothelial tissues has been reported in the literature [229–232]. However, the cloning, expression 
and characterization of CB3 has not yet been performed. 
CB1 and CB2 receptors belong to a large superfamily of heptahelical G protein-coupled receptors 
(GPCR) and couple to Gi/o proteins (for more details, see reviews [171,233,234]). The CB1 receptor is 
mainly expressed in the brain and spinal cord and is thus often referred to as the “brain cannabinoid 
receptor”. CB1 receptors are among the most abundant GPCRs in the brain, and their expression levels 
are similar to the levels of GABA- and glutamate-gated ion channels [235]. The presence of functional 
CB2 receptors in the CNS has provoked considerable controversy over the past few years. Formerly 
considered as an exclusively peripheral receptor [236,237] and often referred to as a “peripheral 
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cannabinoid receptor”, it is now accepted that CB2 is also present in limited amounts and in distinct 
locations in the brain of several animal species, including humans [238,239]. However, the functional 
relevance of this receptor in the CNS is emerging slowly [240]. 
The CB1 receptor displays a wide expression pattern in the developing nervous system and its 
expression corresponds with neuronal differentiation in the embryo from its earliest stages. Several 
studies have described the expression pattern of CB1 receptor mRNA and the distribution of CB1 
receptors in the fetal and neonatal rat brain [212,241–243]. CB1 receptor mRNA levels and receptor 
binding can be detected from GD 14 in rats, which coincides with the time of phenotypic expression of 
most neurotransmitters (for review, see [244]). At this fetal age, CB1 receptors appear to be functional 
because they are already coupled to GTP-binding proteins [241]. The developing human and rat brain 
contain higher levels of CB1 receptors [245,246] compared to the adult brain [212]. However, the 
distribution of CB1 receptors is atypical in the fetal and early neonatal brain, particularly in white 
matter areas [243] and in the subventricular zones of the forebrain [212,241] compared to the adult 
brain [235,246]. This atypical location of CB1 receptors is a transient phenomenon because the 
receptors are progressively acquired during the course of late postnatal development, subsequently 
resulting in the classic pattern of distribution observed in the adult brain [241,243]. The existence of 
CB1 receptors during early brain development suggests the potential involvement of CB1 receptors 
during fetal and early postnatal periods in specific events of CNS development, such as cell proliferation 
and migration, axonal elongation and, subsequently, synaptogenesis and myelinogenesis (for review, 
see [213]). Thus CB1 receptors contribute to the generation of neuronal diversity in specific brain 
regions during early brain development. 
Activation of a cannabinoid receptor promotes its interaction with G proteins, resulting in guanosine 
diphosphate/guanosine triphosphate exchange and subsequent dissociation of the α and βγ subunits. 
These subunits regulate the activity of multiple effector proteins to elicit biological functions. CB1 receptor 
is coupled with Gi or Go proteins. CB1 receptors differ from many other GPCR proteins in that they are 
constitutively active because they are pre-coupled with G-proteins in the absence of exogenously added 
agonists [247]. Among its cellular actions is the inhibition of adenylate cyclase activity [248–250], 
inhibition of N- type voltage-gated channels [251–254], inhibition of N-type, P/Q-type calcium 
channels and D-type potassium channels [250,255], activation of A-type and inwardly rectifying 
potassium channels [256] and inhibition of synaptic transmission [255,257]. On the basis of these 
findings, it has been suggested that CB1 receptors play a role in the regulation of neurotransmitter 
release [255,257]. 
In addition, one of the most interesting research areas is the regulation of neuritogenesis, axonal 
growth and synaptogenesis by CB1 receptors (for references, see recent article [218]). However, the 
molecular mechanisms involved in this process are still unclear. The CB1 receptor activates the MAPK 
pathway [258]. In some cells, CB1 receptor-mediated activation of MAPK was mediated via the  
PI3 kinase pathway [258,259]. AEA, CP, 55,940 and WIN 55,212-2 increased phosphorylation of 
focal adhesion kinase (FAK+6,7) a neural isoform of FAK, in hippocampal slices and in cultured 
neurons [260]. Moreover, CB1 receptor activation stimulated the phosphorylation of the Tyr-397 
residue of FAK in the hippocampus, which is crucial for FAK activation [261] and increased 
phosphorylation of p130-Cas, a protein associated with FAK in the hippocampus. CB1 receptor-stimulated 
FAK-autophosphorylation was shown to be upstream of the Src family kinases [261]. These new 
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downstream effectors of CB1 receptors are most likely to play a role in some forms of synaptic 
plasticity via gene regulation; however, further investigation is required. 
There is evidence that perinatal exposure to cannabinoids modifies the maturation of 
neurotransmitter systems and their related behaviors [213,262–265]. These effects were caused via the 
activation of CB1 receptors, which emerge early in the developing brain [212,213,241,265]. Activity 
in the adult brain of a specific neurotransmitter is the result of a temporally ordered sequence of events 
that occurs during early CNS development. Dysregulation of this pattern may result in alterations in 
some of the functions related to this neurotransmitter. For example, a disturbance in the expression of 
the genes implicated in the synthesis of receptors in a very specific moment of development can  
result in alterations in some of the activities related to the physiological functions of these receptors. 
These alterations may also be a consequence of an increase or decrease in their concentrations or a 
modification in the activity of the CB1 receptor signaling pathways. Administration of cannabinoids, at 
doses similar to those found in marijuana consumers, was found to modify normal neurotransmitter 
development, which likely produced neurobehavioral disturbances. Thus, adult animals that are 
perinatally exposed to cannabinoids exhibit, among other symptoms, long-term alterations in male 
copulatory behavior [266], open-field activity [267], learning ability [268], stress response [269], pain 
sensitivity [270], social interaction and sexual motivation [271], drug seeking behavior [272], 
neuroendocrine disturbances [273] among others (for review, see [262–264,268]). Furthermore, most of 
these neurobehavioral effects were originated by changes in the development of several neurotransmitter 
systems caused by exposure to cannabinoids and most likely through the activation of CB1 receptors 
during critical prenatal and early postnatal periods of brain development.  
During specific periods of development, CB1 receptors might also be expressed in some subpopulations 
of glial cells, which play an important role in neural development. Cannabinoids induce arachidonic 
acid mobilization in cortical glial cells, and this effect was reversed by the selective CB1 receptor 
antagonist, SR141716A [274], suggesting that the CB1 receptor might play a role in neural-glial 
signaling in the brain. This may result in AEA being released from neuronal cells, which might act on 
astrocyte function via the activation of CB1 receptor located in these cells. It has been observed that 
cannabinoid-induced increase in basal and forskolin-inhibited glucose oxidation and phospholipid 
synthesis was observed in cortical glial cells [275] or C6 glioma cells [276]. These effects were 
reversed by pertussis toxin or SR141716A, indicating an involvement of a Gi/Go protein-coupled CB1 
receptor. These studies also suggested that sphingomyelin hydrolysis and mitogen-activated protein 
kinase stimulation were also involved in this metabolic effect [275]. Cannabinoids in hippocampal 
glial cell cultures induced the expression of kros-24, which was reversed by SR141716A [277], 
suggesting the involvement of CB1 receptors. Similarly, acute administration of Δ9-THC (1–10 mg/kg) 
markedly enhanced the proapoptotic properties of ethanol in the neonatal rat brain. However, Δ9-THC 
did not induce neurodegeneration by itself, although neuronal degeneration became disseminated and 
severe when Δ9-THC was combined with a mildly intoxicating ethanol dose. This Δ9-THC and ethanol 
dose combination resembled the massive neurodegeneration observed when ethanol was administered 
alone at much higher doses [278]. In addition, Δ9-THC and co-administration of a low dose of ethanol 
enhanced CB1 receptor levels without affecting CB2 receptor levels in the thalamus and dorsal 
subiculum brain regions. The effect of Δ9-THC on neurodegeneration was mimicked by the synthetic 
cannabinoid WIN 55,212-2 (1–10 mg/kg) and counteracted by the CB1 receptor antagonist 
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SR141716A (0.4 mg/kg). In addition, neonatal CB1 receptor knock-out mice were less susceptible to 
the neurotoxic effects of a low dose of ethanol. Furthermore, the CB1 receptor antagonist SR141716A 
ameliorated the neurotoxic effects of ethanol [278]. 
In our recent studies, we used a higher dose of postnatal ethanol, which induced a massive widespread 
neurodegeneration in postnatal day 7 mouse brains. In addition to enhanced AEA and associated 
biosynthetic enzymes, we also found transcriptional activation of the CB1 receptor gene, which results 
in enhanced levels of CB1 receptor mRNA as well as protein expression in a time-dependent manner 
in cortical and hippocampal brain regions [111]. Interestingly, we found that postnatal ethanol 
treatment of mice enhances acetylation of histone (H4) on lysine 8 (H4K8ace) at CB1R exon1, CB1R 
binding as well as the CB1R agonist-stimulated GTPγS binding in cortical and hippocampal brain 
regions [110]. Pre-administration of SR141716A or genetic ablation of CB1 receptors (KO) prior to 
ethanol treatment prevented neurodegeneration [110,111]. Interestingly, the protective effects of CB1R 
blockade through pharmacological or genetic deletion resulted in normal adult synaptic plasticity and 
learning and memory including social memory in mice exposed to ethanol at P7. The AEA/CB1R 
signaling pathway may be directly responsible for the synaptic and memory deficits associated with 
fetal alcohol spectrum disorders [110,111]. 
The EC signaling pathway responsible for the specific role during brain development has not  
been well characterized. The available literature suggests the participation of ERK 1/2 via a mechanism 
involving the upstream inhibition of Rap1 and B-Raf (for review see [208]). Activation of CB1Rs also 
prevented the recruitment of new synapses by inhibiting the formation of cAMP [221]. Although the 
intracellular signaling events involving mitogen-activated protein kinase (MAPK) coupled to the 
activation of CB1Rs have been shown in embryonic developmental stage [217] and are not known during 
postnatal development, several studies using cell lines have suggested both up- and downregulation of 
MAPK in Δ9-THC-mediated apoptosis [279,280]. Moreover, cannabis use during brain development 
also induced a veriety of deficits that are similar to several specific human developmental disorders [281], 
and may overlap with, those observed in fetal alcohol syndrome [282], which was likely mediated via 
the activation of CB1Rs. 
Our recent study demonstrated a specific role of CB1 receptor-mediated ERK1/2, cAMP response 
element-binding protein (CREB) phosphorylation, AKT and activity-regulated cytoskeleton-associated 
protein (Arc) expression in postnatal ethanol-induced neurodegeneration. P7 ethanol treatment significantly 
reduced pERK1/2, pAKT, pCREB and Arc protein levels but not total ERK1/2 or AKT or CREB 
protein levels in the hippocampus and neocortex. Interestingly, ERK1/2, CREB phosphorylation and 
Arc expression were rescued by SR pre-treatment. However, AKT phosphorylation was not rescued by 
SR pre-treatment. Similarly, CB1R KO mice, which did not show ethanol-induced neurodegeneration, 
provided protection against P7 ethanol-induced inhibition of ERK1/2, pCREB phosphorylation and Arc 
expression but failed to rescue the inhibition of AKT phosphorylation. Thus, P7 ethanol-activated 
CB1R-induced neurodegeneration was regulated by the AEA/CB1R/pERK1/2/pCREB/Arc cascade 
but not by the PI3-kinase/AKT pathway in the developing brain [110,111] (Figure 2). 




Figure 2. A proposed model suggesting that AEA/CB1R/ERK1/2/pCREB/Arc signaling 
regulates ethanol-induced neurodegeneration, resulting in neurobehavioral deficits in adult 
mice. P7 ethanol-enhances AEA levels (postsynaptic neuron) through transcriptional activation 
of NAPE-PLD and GDE1 enzymes. AEA acting through CB1Rs (AEA tone) (presynaptic 
neuron) may result in decreased glutamate release, which causes N -Methyl-D-aspartate 
(NMDA) receptor hypofunction, ERK1/2 and cAMP response element-binding protein 
(CREB) hypophosphorylation deficits in Arc expression and leads to neonatal 
neurodegeneration (condensed chromatin balls, electron microscopic image). Previous studies 
have shown that CB1R activation inhibits NMDA receptor function in several experimental 
models [283,284] and ethanol was shown to inhibit glutamatergic neurotransmission via 
CB1 receptor activation [285]. These events during postnatal development may disrupt  
the refinement of neuronal circuits [112,123] and lead to long-lasting deficits in synaptic 
plasticity and memory in adult animals. The inhibition of CB1Rs (AEA tone) prevents 
pERK1/2, CREB hypophosphorylation, deficits in Arc expression and neonatal 
neurodegeneration (Tau and caspase-3 cleavage), which results in normal neurobehavioral 
function in adult mice. Genetic ablation of the CB1R does not affect NMDA receptor 
antagonist-induced apoptosis, but does provide protection against ethanol-induced neonatal 
neurodegeneration, synaptic and memory deficits in adult mice. Thus, the putative 
AEA/CB1R/pERK1/2/pCREB/Arc signaling mechanism may have a potential regulatory 
role in neuronal function in the developing brain and may be a valuable therapeutic target 
for FASD. 
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During periods of development when the brain experiences a growth spurt, blockade of the  
NMDA receptor for a few hours has been found to trigger massive and widespread apoptotic 
neurodegeneration in the rodent brain [286]. NMDA receptor antagonists were the most effective in 
inducing apoptosis in the rat forebrain at P7. Thus, during this developmental period, the survival of 
NMDA receptor-expressing neurons was dependent on the glutamatergic input being regulated within 
narrow time periods [286]. Endocannabinoids and cannabinoids are well known to affect glutamatergic 
signaling [287,288], and therefore, ethanol-induced endocannabinoids [111,285] or cannabinoid-induced 
alterations in glutamate levels [289–291] might contribute to neonatal neurodegeneration or lasting 
behavioral deficits [111,112,123] observed after binge-like ethanol exposure during this specific 
vulnerable period of brain development. Furthermore, pharmacological blockade or genetic deletion of 
CB1 receptors removed the endocannabinoid-mediated inhibition of glutamate release by ethanol, resulting 
in a lack of ethanol-induced neurodegeneration (Figure 2). Thus, CB1 receptors served as good 
candidate targets for modulating NMDA receptor function in developmental disorders. Interestingly, 
NMDA receptor antagonists were able to induce apoptotic neurodegeneration in CB1 receptor KO 
mice [111], further strengthening the mechanism by which postnatal ethanol exerts its deleterious 
effects in the developing brain (Figure 2). Findings obtained from neonatal rats suggested  
that ethanol might actually affect CA3 pyramidal neurons via inhibition of postsynaptic  
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPARs), which result in a decrease 
in glutamatergic release [292]. Moreover, this study was consistent with the study conducted by  
Twitchell et al. in 1997 in which exogenous cannabinoids inhibited glutamatergic release by activating 
CB1R-mediated inhibition of N-type and P/Q-type calcium channels [283] and might be responsible 
for the enhanced susceptibility of the immature brain to ethanol neurotoxicity [278] and long-lasting 
learning and memory deficits [108–112,293]. 
While the molecular mechanism is still unclear, ethanol treatment during early brain development 
caused deficits in synaptic function [294], which persisted into adulthood [108–112,293]. It is also  
possible that ethanol-enhanced AEA-CB1 receptor tone disrupts the refinement of neuronal circuits, 
leading to persistent synaptic dysfunction. This could explain why some cortical maps [295–298] and 
olfacto-hippocampal networks [112,123] are altered in FASD models. Consistent with this notion,  
pre-administration of CB1 receptor antagonist (SR141716A) completely rescued the P7  
ethanol-induced defects in the LTP magnitude of field excitatory postsynaptic currents (fEPSPs), both in 
the initial induction and maintenance. Interestingly, the genetic deletion of CB1 receptors provided 
complete protection against P7 ethanol-induced defects in LTP. However, CB1R KO mice exhibited an 
enhanced LTP magnitude compared to WT or normal C57BL/6J saline-treated mice [109–111] as 
observed in other studies [299,300]. In addition, ethanol treatment at P7 impaired object recognition, 
spatial and social interaction memory performance and was rescued in mice treated with SR [109–111]. P7 
ethanol administration showed no significant effects on adult CB1R WT or KO mice exploration times 
in the object recognition memory (ORM) task. Because deletion of CB1 receptors has been shown to 
enhance their ability to perform better on a learning task [300], we found enhanced object recognition 
performance and spatial memory in CB1 receptor KO mice compared to WT mice. Furthermore, CB1 
receptor KO mice provided protection against P7 ethanol-induced deficits in object recognition memory 
performance, spatial memory and social interaction memory as observed in LTP. Therefore, suppression of 
CB1 receptor function via pharmacological blockade or genetic deletion of CB1 receptors prior to 
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postnatal ethanol exposure prevented synaptic and memory deficits in adult mice. Taken together, 
these findings emphasize the importance of this mechanism in the understanding and development of 
therapeutic strategies used to treat FASD. 
It is also possible that activation of CB1 receptors during the critical period of brain development 
can affect both the glutamatergic system and the development of multiple neurotransmitter systems, 
including the catecholaminergic, serotonergic, GABAergic and opioid systems [213,301,302], resulting 
in an altered hippocampal circuit and long-term behavioral deficits [303] (Table 2). Activation of CB1 
receptors during postnatal development, although less well investigated, may also result in long-term 
behavioral deficits [304] mediated through NMDA receptor function [111]. However, further research 
is required to establish the effect of CB1 receptor activation during brain development on the function  
of multiple neurotransmitter systems, which may cause lasting morphological changes underlying the 
synaptic and memory deficits. 
Table 2. Summary of Long-lasting behavioral abnormalities found in animals as consequences 
of cannabinoid exposure and CB1 receptor activation during brain development. 
 Cannabinoid Exposure References 
Learning and memory 
Learning deficits in the Morris water maze. [305] 
Impairment in the inhibitory avoidance test and impaired  
olfactory short-term memory in the social discrimination task. 
[306] 
Poorer performance in homing behavior  
and impaired active avoidance performance. 
[307] 
Disruption of memory retention in the passive avoidance task. [308] 
Reduced novel object recognition. [309,310] 
Impaired working memory on Y maze. [311] 
Reduced social interaction. [309,310] 
2. Conclusions 
In summary, several molecular mechanisms are expected to contribute to the damaging effects  
of prenatal alcohol exposure on the developing fetus. These events including endocannabinoid 
mechanisms contribute to impaired development and function of neuronal communication and circuit 
formation. These alcohol-induced deficits result in long-lasting abnormalities in neuronal plasticity and 
learning and memory and can explain many of the neurobehavioral abnormalities found in FASD 
(Figure 3). The physiological role of the EC system during early brain development has not yet been 
fully elucidated. The search for additional functions is underway, and the strategies used to identify 
them are improving. However, there is not sufficient attention focused in this direction. Modulation of 
this system using pharmacological and gene knockout approaches support a role for the EC system in 
learning and memory, emotion and anxiety, reward, eating, nociception and motor systems, among 
others; however, none of these behavioral responses are critically dependent on the veracity of the EC 
system, indicating that it functions in a modulatory or facilitatory manner, thus making it a highly 
attractive target for the development of therapeutic agents to treat FASD. 
  




Figure 3. Molecular events leading to loss of learning and memory as found in FASD. 
Depending on the developmental stage, pattern, concentration and duration of prenatal 
ethanol exposure can lead to molecular alterations (for example, activity of growth factors, 
changes in the regulation of gene expression, changes in adhesion, changes in 
endocannabinoid system) and impaired in neuronal communication and circuit formation. 
These events may lead to several transient and permanent changes in the hippocampus, 
including molecular changes, modifications in synaptic plasticity, morphological changes 
and neuronal loss. These prenatal ethanol-associated changes in the brain can potentially 
induce deficits in learning-and-memory processes found in the adult animals of FASD. 
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acid-A receptor; MAPK, mitogen-activated protein kinase; Δ9-THC, delta-9-tetrahydrocannabinol; AEA, 
arachidonylethanolamide (anandamide); 2-AG, 2-arachidonylglycerol; NADA, N-arachidonyl-dopamine; 
VR1, vanilloid receptor type 1; NAPE-PLD, N-acylphosphatidylethanolamine-specific phospholipase D; 
GDE1, glycerophosphodiesterase; ABHD4, abhydrolase domain 4; PTPN22, phosphatase; AMT, AEA 
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